netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 30 of 96

Older Oldest

Details
LDL Link Added : NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer : https://www.nice.org.uk/guidance/ta939
14/03/2024 15:21:25
(DavidS )
UPD sitematrix Changed from 0 to
14/03/2024 15:20:52
(DavidS )
UPD FurtherInformation Changed from
14/03/2024 15:20:52
(DavidS )
UPD Pembrolizumab (Keytruda®) NICE TA938
14/03/2024 15:20:52
(DavidS )
UPD Published from Draft Mode
18/01/2024 10:32:05
(LoweryM )
UPD sitematrix Changed from 0 to
12/01/2024 13:41:31
(DavidS )
UPD FurtherInformation Changed from
12/01/2024 13:41:31
(DavidS )
UPD Pembrolizumab (Keytruda®) NHSE SSC2561
12/01/2024 13:41:31
(DavidS )
LDL Link Added : NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency : https://www.nice.org.uk/guidance/ta914
11/01/2024 11:34:54
(DavidS )
UPD sitematrix Changed from 0 to
11/01/2024 11:34:29
(DavidS )
UPD isDraft Changed from N to Y
11/01/2024 11:34:29
(DavidS )
UPD FurtherInformation Changed from
11/01/2024 11:34:29
(DavidS )
UPD Pembrolizumab (Keytruda®) NICE TA914 & NHSE SSC2593
11/01/2024 11:34:29
(DavidS )
UPD Published from Draft Mode
20/11/2023 16:37:08
(LoweryM )
LDL Link Added : NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer : https://www.nice.org.uk/guidance/ta904
20/11/2023 13:09:49
(DavidS )
UPD sitematrix Changed from 0 to
20/11/2023 13:09:23
(DavidS )
UPD isDraft Changed from N to Y
20/11/2023 13:09:23
(DavidS )
UPD FurtherInformation Changed from
20/11/2023 13:09:23
(DavidS )
UPD Pembrolizumab (Keytruda®) NICE TA904
20/11/2023 13:09:23
(DavidS )
UPD Published from Draft Mode
10/10/2023 16:12:01
(LoweryM )
UPD sitematrix Changed from 0 to
10/10/2023 16:11:50
(LoweryM )
UPD Pembrolizumab (Keytruda®) approved
10/10/2023 16:11:50
(LoweryM )
LDL Link Added : NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer : https://www.nice.org.uk/guidance/ta885
10/10/2023 13:42:47
(DavidS )
UPD sitematrix Changed from 0 to
10/10/2023 13:41:19
(DavidS )
UPD isDraft Changed from N to Y
10/10/2023 13:41:19
(DavidS )
UPD FurtherInformation Changed from
10/10/2023 13:41:19
(DavidS )
UPD Pembrolizumab (Keytruda®) NICE TA885
10/10/2023 13:41:19
(DavidS )
LDL Link Added : MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection : https://www.gov.uk/drug-safety-update/nivolumab-opdivo-pembrolizumab-keytruda-reports-of-organ-transplant
11/07/2023 18:30:50
(dmcdermott )
UPD sitematrix Changed from 0 to
17/11/2022 14:27:42
(DavidS )
UPD FurtherInformation Changed from
17/11/2022 14:27:42
(DavidS )

 

 

netFormulary